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ABSTRACT
Background: Current response criteria in rheumatoid
arthritis (RA) usually assess only three patient-reported
outcomes (PROs): pain, functional disability and patient
global assessment. Other important PROs such as fatigue
are not included.
Objective: To elaborate a patient-derived composite
response index for use in clinical trials in RA, the RA
Impact of Disease (RAID) score.
Methods: Ten patients identified 17 domains or areas of
health relevant for inclusion in the score, then 96 patients
(10 per country in 10 European countries) ranked these
domains in order of decreasing importance. The seven
most important domains were selected. Instruments were
chosen for each domain after extensive literature research
of psychometric properties and expert opinion. The
relative weight of each of the domains was obtained from
505 patients who were asked to ‘‘distribute 100 points’’
among the seven domains. The average ranks of
importance of these domains were then computed.
Results: The RAID score includes seven domains with
the following relative weights: pain (21%), functional
disability (16%), fatigue (15%), emotional well-being
(12%), sleep (12%), coping (12%) and physical well-being
(12%). Weights were similar across countries and across
patient and disease characteristics. Proposed instruments
include the Health Assessment Questionnaire and
numerical ratings scales.
Conclusion: The preliminary RAID score is a patient-
derived weighted score to assess the impact of RA. An
ongoing study will allow the final choice of questionnaires
and assessment of validity. This score can be used in
clinical trials as a new composite index that captures
information relevant to patients.
Rheumatoid arthritis (RA) is traditionally assessed
by physical examination by a physician, by
laboratory tests and radiographs, in keeping with
a ‘‘biomedical model,’’ the dominant paradigm of
20th century medicine. However, since the start of
the new millennium there has been growing
interest in assessment of RA from the patient’s
perspective. Patient-reported outcomes (PROs)
have been found to be as informative as joint
counts, radiographic and laboratory data for the
assessment of baseline status, change during
interventions, and are predictive of long-term
outcomes.1–8 Current assessment of RA takes into
account some PROs—namely, patient assessment
of pain, functional disability and/or patient global
assessment. These elements are recognised both by
the American College of Rheumatology (ACR)9 10
and the European League Against Rheumatism
(EULAR),11 and are assessed in the ACR criteria,12
the Disease Activity Score (DAS)13 as well as more
recent measures such as the Simplified Disease
Activity Index (SDAI), the Clinical Disease
Activity Index (CDAI)14 15 and the mean overall
index of RA (MOI-RA)16 and two PRO composite
measures, the patient activity scale (PAS)17 and the
Routine Assessment of Patient Index Data 3
(RAPID3).18 Formal quantitative joint counts, an
integral part of the DAS, SDAI and CDAI, are
frequently not performed in routine clinical prac-
tice.19 The RAPID3 has been shown to be as
efficient as the DAS and CDAI to detect changes in
clinical trials,18 20 and to be correlated with DAS
and CDAI in usual clinical settings.21 Current PRO
composite scores therefore appear very useful.
However, these scores only include three PROs,
while other dimensions of health may be impor-
tant from the patient’s perspective and are
included in clinical questionnaires such as the
multidimensional Health Assessment
Questionnaire (HAQ).21 More complex generic
quality of life instruments such as the Short
Form (SF)-3622 and the Arthritis Impact
Measurement Scale (AIMS2)23 capture information
regarding several other domains including mental
health and social functioning.
Over the last few years, expert panels and focus
groups have indicated that the patient’s perspec-
tive is not adequately reflected by only the three
PROs: pain, function and patient’s global. The
Outcome Measures in Rheumatology Clinical
Trials (OMERACT) international research meet-
ings in 200224 and several focus group studies have
indicated that other PROs are important for people
with RA, such as fatigue, well-being and sleep
pattern.25–30
The objective of the present work, under the
aegis of EULAR, is to elaborate and validate a
composite response score for clinical trials in RA
based on patients’ perception of the impact of
the disease on domains of health: the patient-
derived preliminary RA Impact of Disease (RAID)
score. This paper addresses the elaboration of the
score.
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METHODS
Step 1: Identification and selection of candidate domains for the
RAID score
Initial choice of domains
Ten patients with RA, one from each of 10 European countries,
met in Zurich in March 2007. All had definite RA according to
the ACR criteria,31 spoke English and were selected by the
principal investigators in each country. They had varying
experience in research partnership; three are also part of the
OMERACT patient group.
The patients were presented with an extensive literature
review on domains of health in RA. During a ‘‘focus group’’
type meeting and in three successive sessions, the participants
identified domains of health important for the patient based on
their personal experience.
Ranking of domains
The steering committee had arbitrarily decided, on the basis of
feasibility, to include in the composite score a maximum of seven
domains. After the first step the resulting number of domains was
too large so, to reduce the number of domains and to obtain better
representativeness, a ‘‘ranking’’ strategy was designed.
One hundred patients with RA (10 in each country) were
contacted by the principal investigator and/or by the patient
representative. These people all had definite RA; there were no
other selection criteria.
The names of the domains obtained in the previous step were
translated into 12 languages with a brief explanation and
presented as a list in random order. The participants were asked
to rank the domains in order of decreasing importance by giving
a number between 1 (most important) and 17 (least important)
to the 17 domains. No other data were collected at this stage
(May–June 2007). The seven highest-ranked domains were
retained in the RAID score.
Step 2: Identification of instruments to measure the candidate
domains
The participants were the steering committee, the principal
investigators and two external experts (GAW and JPD). This was
a data-driven process. One or several items, instruments or whole
questionnaires were selected for each domain by consensus after
an extensive literature review of published questionnaires, their
psychometric properties32 and their frequency of use.33 When
there were no available validated instruments, a numerical rating
scale (NRS) was formulated by the group and validated with the
10 patients with arthritis who participated in the first step.
Validated translations of the instruments were then collated; if
these translations were not available, a translation/validation
process was performed into 12 languages (Estonian, Dutch,
Finnish, French, German, Greek, Italian, Norwegian, Romanian,
Russian, Spanish, Turkish). The process included two separate
translations, simple consensus, back-translation and cross-
cultural validation by a multidisciplinary consensus committee,
followed by pretesting on five patients.34 35
Step 3: Relative weight of the candidate domains to be included
in the score
To allow aggregation of results into a single composite criterion,
it was necessary to determine the relative importance of the
different domains of health. It was decided that the relative
importance should be based on patients’ opinion,36 so a
weighting strategy was designed.
It was planned to include 500 patients (50 from each
country). Selection criteria were definite RA,31 ability to fill in
a questionnaire and signed informed consent. Between June and
November 2007, eligible patients filled in a questionnaire and
were asked to ‘‘distribute 100 points’’ among the seven domains
according to a method described by Ruta et al37 and modified for
our purposes. The question was: ‘‘We want you to indicate how
much your RA impacts your health in the following selected
domains or dimensions; please distribute 100 points between
the domains according to their impact’’. In one country the
arithmetic appeared too complicated and the process was
performed with the same question but by asking patients to
distribute 100 matches between the seven domains, materialised
by papers.
The following other variables were also collected by the
questionnaire: demographic data (age, sex, symptom duration,
work status), Health Assessment Questionnaire (HAQ),38 pain,
Table 1 Seventeen domains of health ranked for importance by 96 patients with RA
Domain* Mean (SD) rank Median rank
Order of
domains
by median
Patients giving
rank 1–7
to the domain (%)
Patients giving
rank 1–3
to the domain (%)
Pain 4.3 (4.2) 2 1 78.1 59.4
Functional disability 6.3 (3.9) 5.5 2 64.6 30.2
Fatigue 6.7 (4.2) 6 3 61.4 26.0
Physical well-being 8.3 (4.9) 9 5 44.8 24.0
Coping 8.8 (4.4) 9 5 41.7 16.7
Sleep 8.9 (4.8) 8 4 45.8 13.5
Emotional well-being 8.9 (4.0) 9 5 33.3 8.3
Being a burden to others 9.0 (4.6) 9.5 9 40.6 15.6
Family life 9.3 (5.3) 10 11 38.5 20.8
Satisfaction with health
care
9.5 (5.1) 9 5 37.5 18.7
Anxiety 9.5 (4.5) 9.5 9 37.5 12.5
Ability to fulfil social role 9.5 (4.6) 10 11 35.4 11.5
Depression 10.0 (4.5) 10 11 32.3 9.4
Drug side effects 10.1 (4.8) 11 15 33.3 8.3
Professional life 10.2 (4.8) 10 11 33.3 12.5
Sexuality 11.2 (5.2) 12 16 23.9 10.4
Socioeconomic issues 11.5 (4.6) 13 17 27.1 5.2
*Domains are ordered by mean rank.
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patient global assessment and fatigue on visual analogue scales
(VAS) and SF-36.22
Mean and median weights for each domain were computed
and linearly transformed to a 0–100 range. Ranks of importance
of domains (based on these points) were identified in each
participating patient; for example, if a domain received 20
points and was the second most important domain it was given
rank 2, whereas it was given rank 4 if the points were similar
but it was the fourth domain. Mean and median ranks were
then also computed for the whole group of 500 patients and
linearly transformed to a 0–100 range. It was decided to use
these ranks as the basis for the final weights.
Step 4: Assessment of the generalisability of the preliminary
RAID
Using the data obtained from the elaboration of the RAID (both
ranking and weighting), the extrinsic applicability of the relative
importance attributed to the domains was assessed.
Data from the ranking process were used to compare ranks of
importance of domains across countries.
c Groups of domains: domains were analysed in groups according
to the original categorisation performed by the 10 initial
patients with some modifications: fatigue was considered as
a domain in itself as its importance is high in the published
qualitative literature.24 25 27 For each patient, a group of domains
was attributed ‘‘high priority’’ if at least one of the domains in
the group was given rank 1, 2 or 3 (out of a possible 17).
c Countries: the percentage of patients attributing high
priority to each group of domains was compared between
countries using the Fisher exact test.
c Groups of countries: countries were classified as high or low
gross domestic product (above or below the median)
according to 2005 data. High priority groups of domains
were compared between these groups of countries using the
Fisher exact test.
Data from the weighting process were used to analyse weights
across demographic and disease characteristics. Weights were
analysed as binary measures (dichotomised by median). By multiple
component analysis, demographic (age, sex, disease duration) and
activity/severity data (pain VAS, HAQ, fatigue VAS, global
assessment VAS, SF36) were projected on the axes created based
on dichotomised weights to assess potential relationships.
RESULTS
Step 1: Identification and selection of candidate domains for the
RAID score
Initial choice of domains
The 10 patients with RA held three sessions to identify 17
domains. In the first session 80 different areas/words were
reported; in the second session these areas were categorised into
physical, psychological, social and general dimensions and
simultaneously reduced to 32 areas (see Appendix 1 in the
online supplement); and in the third session the patients with
arthritis and the professionals together performed a regrouping
of similar concepts which led to 17 domains.
Ranking of domains
The results of the ranking of the 17 domains by 96 patients are
shown in table 1, including the mean and median ranks. The
percentage of patients attributing high ranks to each domain is
shown in the last two columns.
The following seven highest ranked domains were selected for
the RAID score: pain, functional assessment, fatigue, sleep
disturbance, physical well-being, emotional well-being and
coping (table 2). Although slightly less prioritised, emotional
well-being was selected because it potentially ‘‘covers’’ several
concepts rated highly (ie, being a burden to others and anxiety).
Step 2: Identification of instruments to measure the candidate
domains
A simple question (assessed by NRS) and often a more complete
validated instrument/questionnaire were selected for each
domain (see Appendix 2 in online supplement). The final choice
of instruments will be performed based on the ongoing
validation study. For each domain a simple carefully worded
question39 scored by NRS is proposed. For pain, the NRS is
compared with the two pain questions issued from the SF-36.22
For functional assessment, the NRS is compared with the 20-
question HAQ38 and with the modified HAQ (8 questions).40
Sleep NRS is assessed against the four questions of the Medical
Outcome Study (MOS) sleep disturbance subscale,41 and coping
is assessed by NRS and a 20-question coping questionnaire
modified from a validated coping questionnaire.42
Table 2 The seven domains included in the preliminary RAID score, corresponding instruments and the
weight attributed to each domain by 505 patients
Domain Questionnaire
Mean (SD) weight/
100
Median (IQR) weight/
100 Ranked weight/100
Pain NRS 21 (23) 12 (12–24) 21
Pain questions of SF36
Function NRS 19 (16) 15 (7–24) 16
HAQ
Modified HAQ
Fatigue NRS 17 (15) 12 (6–24) 15
Emotional well-being NRS 12 (14) 12 (0–17) 12
Sleep NRS 11 (12) 12 (0–18) 12
MOS sleep disturbance
subscale
Coping NRS 11 (12) 12 (0–18) 12
Coping questionnaire
Physical well-being NRS 9 (12) 7 (0–12) 12
IQR, interquartile range; SD, standard deviation; HAQ, Health Assessment Questionnaire; MOS, Medical Outcome Study subscale
(4 questions); NRS, numerical rating scale; Coping questionnaire: 20 questions derived from a validated coping questionnaire.42
Weights are expressed as linearly transformed to a 0–100 range. The ranked weight was obtained by analysing the relative ranks
of importance, then linearly transforming the result to a 0–100 scale.
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Step 3: Relative weight of the candidate domains to be included
in the score
In total, 505 patients participated in the weighting process
(table 3). Their mean (SD) age was 55.9 (13.2) years, mean (SD)
disease duration was 14.5 (10.3) years, mean (SD) HAQ score was
1.23 (0.78) and 82% were women. The relative ranked weights for
aggregation into a composite score were as follows (table 2): pain
21%, functional disability 16%, fatigue 15%, and emotional well-
being, sleep, coping and physical well-being 12% each.
Step 4: Assessment of the generalisability of the preliminary
RAID
Data from the ranking process
The 17 domains were analysed in five groups (table 4). At least
one domain in each group was attributed high priority ranking
with the following percentages: physical group, 81% (range
across countries 40–100%); psychological group, 47% (range
30–70%); socioeconomic group, 40% (range 10–83%); fatigue,
26% (range 10–40%); and general group, 30% (range 10–60%).
There were no significant differences across countries or groups
of countries except for the physical group of domains, which
was more often highly rated in countries with lower gross
domestic product (92% vs 70%, p = 0.007, table 4).
Data from the weighting process
The first three axes contributed 68.6% to the total inertia. The
domains that most contributed to the construction of axis 1 and
which were best and similarly represented by that axis were
pain and emotional well-being. A high score allocated to
emotional well-being appeared to be associated with a higher
score for pain. The variables that most contributed to the
construction of axis 2 were functional disability, sleep and
fatigue, the first two domains being best represented by axis 2.
It appeared that higher scores for function were related to lower
scores for the other two domains and vice versa. Physical well-
being and sleep contributed most to the construction of axis 3.
Demographic and disease variables were projected on the
axes: these variables were on the centre (data not shown),
indicating that the demographic and disease variables did not
explain the weights attributed to the different domains.
DISCUSSION
In this report a preliminary patient-derived score to assess the
impact of RA from the patients’ perspective is proposed. The
score includes seven domains prioritised by patients. The
domains of highest importance were pain, functional disability
and fatigue; the four other domains were emotional and
physical well-being, sleep disturbance and coping. The similarity
of patient-perceived impact across different countries and
different patient and disease characteristics strengthens the
relevance and generalisability of the preliminary RAID score.
No single variable is considered sufficient to assess RA disease
activity and composite indices are well adapted to this situation.
Composite indices such as the DAS, the SDAI, the CDAI, MOI-
RA, PAS and RAPID3 have been validated.13–18 However,
concerns have been raised that these indices may not adequately
capture all patient-relevant data, which was the basis for the
development of this new tool. However, patient-reported data
are strongly colinear, so adding more variables may not add to
information over the existing indices on a group level, which
will need to be further explored.
The impact of RA is perceived by patients in different
domains of health. Relevant domains were selected through a
Table 3 Description of the 505 patients participating in the weighting
process
Characteristic
Mean (SD), (range)
or N (%)*
Range across
countries of mean
(SD) or %{
Female, N (%) 411 (82.5%) 72.0–97.3%
Age (years) 55.9 (13.2), (20.3–86.9) 48.5 (15.1)–60.4 (15.3)
Symptom duration (years) 14.5 (10.3), (1.3–57.0) 12.3 (10.6)–16.8 (11.0)
Formal education (years) 11.5 (4.5), (0–20) 7.4 (3.7)–14.5 (3.4)
Employed full-time or part-time
when symptoms started, N (%)
293 (58.9%) 48.0–72.0%
Currently employed full-time or
part-time, N (%)
149 (28.6%) 14.0–54.0%
Work disabled, N (%) 190 (41.0%) 30.4–68.1%
HAQ 1.23 (0.78), (0–3) 1.00 (0.74)–1.56 (0.80)
Pain VAS over 1 week (0–100) 44 (29), (0–100) 30 (22)–55 (25)
Patient global assessment VAS
(0–100)
43 (25), (0–100) 32 (22)–50 (27)
Disease activity assessment over
6 months VAS (0–100)
45 (27), (0–100) 36 (24)–60 (24)
Fatigue VAS over 1 week (0–100) 46 (28), (0–100) 38 (27)–51 (32)
Morning stiffness duration (min) 70 (130), (0–360) 28 (31)–87 (75)
SF36 aggregated physical score 34.4 (10.4), (10.3–62.0) 28.1 (10.1)–37.4 (11.0)
SF36 aggregated emotional score 46.5 (12.2), (13.4–71.4) 41.6 (12.4)–51.6 (11.6)
*Results are presented as mean (SD) unless otherwise stated. Percentages are % of
available data.
{Range of means or percentages: minimum and maximum values for means or
percentages observed in participating countries.
HAQ, Health Assessment Questionnaire; SF36, Short Form 36 generic quality of life
scale; VAS, visual analogue scale.
Table 4 Attribution of high priority ranking to groups of domains by 96 patients: comparisons across countries
Group of domains Domains included
Percentage with
high priority
Range of
percentages
Percentage in 5
countries with
higher GDP
Percentage in 5
countries with
lower GDP p Value
Physical Pain, functional disability,
physical well-being, sleep
disturbance
81 40–100 70 92 0.007
Psychological Depression, anxiety,
emotional well-being, feeling
a burden to others, coping
47 30–70 50 44 0.7
Socioeconomic Professional life, social role,
family life, socioeconomic
issues
40 10–83 39 40 0.9
General Sexuality, drug side effects,
satisfaction with health care
30 10–60 30 30 0.9
Fatigue Fatigue 26 10–40 28 24 0.6
GDP, gross domestic product/capita in 2005.
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patient-derived process, first by a focus group type meeting
with 10 patients followed by a ranking process including 96
patients. The final selection of domains is in keeping with the
published qualitative literature as pain, functional disability and
fatigue appear to be of utmost importance to many patients24–30
and were the first three domains in the ranking process. Only
these three domains obtained consistently high ranks for
impact. Pain and functional disability are part of the RA Core
Set9 and are regularly cited as important by patients with
RA.25 27–29 Fatigue is a frequent aspect of RA, as initially reported
by the OMERACT patient group.24 25 Other domains reported in
the literature as important include well-being, sleep disturbance,
coping, social life, professional status (ability to work) and
satisfaction with health care.24–30 In the present study, sleep,
physical and emotional well-being and coping were also
selected. Based on the ranking results, however, it can be seen
that these domains did not stand out among the other domains.
The International Classification of Functioning, Disability and
Health (ICF) is a generally accepted framework to assess the
biopsychosocial model of disease.29 It is interesting to note that
the domains selected in the RAID were also selected in ICF-
based focus groups,29 except for well-being. Patient global
assessment was not selected by the patients with RA in the
present study; it is possible that the notions of emotional and
physical well-being translate ‘‘patient global’’ into terms more
understandable for patients.
In the ranking process the physical group of domains was
most often ranked highly, followed by the psychological group.
Patient perception of the impact of RA on the physical group of
domains was ranked higher in countries with lower gross
domestic product, possibly because many patients in these
countries still experience remarkable functional disability.43
Interestingly, other impacts including psychological dimensions
and fatigue were similar across countries. The domains selected
for entry into the RAID score therefore appear relevant for
patients across countries.
Not all domains selected and prioritised by patients can easily
be measured. For example, well-being—though recognised as an
important concept24 25—is not currently assessable. In such cases
specific questions were elaborated by the authors. In other cases
such as functional disability, it was impossible to select only one
questionnaire based on the available literature. Coping was also
a challenge as many coping questionnaires are available but
there is no consensus on which is the most appropriate to use in
RA.44 Thus, in all, 12 instruments were selected for the seven
domains. The final choice of one instrument per domain will be
made after the ongoing validation study.
The weights attributed to each domain were based on the
patients’ scoring of the importance of the domains by name or
description. When analysing weights according to baseline
patient and disease characteristics, it appeared that patients
rated the domains independently of their demographic char-
acteristics. Thus, gender did not significantly influence the
results, nor did age or disease duration. The weights attributed
to the domains were also independent of the patients’ personal
status. For example, it seems that patients are able to
distinguish their current level of pain from the impact they
attribute to pain in RA, even if previous studies have indicated a
statistical association between perceived pain intensity and pain
as a prioritised area for improvement.45 46 However, the overall
independence between health status and perceived impact on
RA support the notion that the selected seven domains are
relevant for patients across demographic and disease activity/
severity characteristics. We recognise that other approaches
could have been applied to weigh the domains, such as a
statistical evaluation of the relative importance of the actual
scores of patient responses to questionnaires concerning
function, pain, fatigue and other domains.
The ongoing next step is the validation of the preliminary
RAID score in a large European study. Objectives of the ongoing
study include assessment of psychometric properties of the
RAID score, including its face, construct and external validity
(and correlation with other validated scores) and discrimination,
according to the OMERACT filter.47 A final choice of domains
will be performed based on these results. Coping or other
domains will be excluded if psychometric properties are
insufficient. A final choice of instruments will also be
performed. Secondary objectives will be the elaboration of
cut-off points to provide a patient-acceptable symptom state
and minimal clinically important improvement for the RAID.48
The RAID is viewed as an additional instrument for the
assessment of RA in clinical trials, giving supplementary
information on patient-relevant domains.
This study has strengths and weaknesses. Weaknesses include
the necessary selection of some patients to elaborate the score,
as they may not be representative; however, it should be noted
that the characteristics of the patients participating in the
weighting study (including their education level) were very
similar to those of patients participating in an unselected cross-
sectional study, the QUEST-RA.43 Another limitation was the
decision, for feasibility reasons, to limit the number of domains
to seven. Strengths include the central involvement of patients
for elaboration of the RAID and the inclusion of patients with
RA from 10 countries with different cultures and socioeconomic
backgrounds. Furthermore, the methodology used to obtain
patient-derived weights is innovative and could be applied to
other conditions.
In conclusion, this study enabled us to propose a preliminary
patient-derived weighted score to assess the impact of RA. We
consider that this RAID score will be of value in clinical trials as
a new composite index that captures information which is
relevant for patients, although its value still needs to be
established in comparison with existing PRO indices. The
process is in itself important, by involving patients and
rheumatologists from 10 different countries.
Author affiliations: 1 Paris Descartes University, Medicine Faculty, UPRES-EA 4058,
APHP, Rheumatology B Department, Cochin Hospital, Paris France; 2 Epidemiology and
Statistics Department, Montpellier Medicine Faculty, Montpellier, France; 3 Research
Center of Rheumatic Diseases, ‘‘Sf Maria’’ Hospital, University of Medicine and
Pharmacy ‘‘Carol Davila’’, Bucharest, Romania; 4 Rheumatology, Clinical Immunology
and Allergy, University of Crete, Faculty of Medicine, Heraklion, Greece; 5 EULAR
standing committee of People with Arthritis/Rheumatism in Europe (PARE), Zurich,
Switzerland; 6 Research Unit, Spanish Foundation of Rheumatology, Madrid, Spain;
7 Rheumatology, VU University Medical Center and Jan van Breemen Institute, The
Netherlands; 8 Department of Internal Medicine 3, University of Erlangen-Nuremberg,
Erlangen, Germany; 9 University of Gazi, Department of Physical Medicine and
Rehabilitation, Division of Rheumatology, Ankara, Turkey; 10 Department for Research
and Education, Ulleval University Hospital, Oslo, Norway; 11 University of Bristol,
Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK; 12 Rheumatology
Department, Hospital Universitario La Paz, Madrid, Spain; 13 Department of Medicine,
Division of Rheumatology AOUC, Denothe Centre, University of Florence, Firenze, Italy;
14 Rheumatology Department, Tallinn Central Hospital, Estonia; 15 Jyva¨skyla¨ Central
Hospital, Jyva¨skyla¨, Finland; 16 University of Ottawa Heart Institute, Ottawa, Ontario,
Canada; 17 Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway;
18 Faculty of Medicine, University of Oslo, Oslo, Norway
Acknowledgements: The authors wish to acknowledge all personnel who
participated in data collection and in particular, in Crete, Dr Herakles Kritikos and Eva
Choustoulaki.
Funding: EULAR grant CLI.013.
Competing interests: None.
Extended report
1684 Ann Rheum Dis 2009;68:1680–1685. doi:10.1136/ard.2008.100271
Ethics approval: All applicable regulations were respected and the project was
accepted by ethical committees in participating countries.
This project, supported financially by EULAR, was convened by TKK, facilitated by LG,
and has as steering committee one other rheumatologist (MD), two patients with RA
(SC and MdW), one epidemiologist (LC) and one allied health professional (TH). Ten
countries were involved in the elaboration of the RAID: Estonia, France, Greece, Italy,
the Netherlands, Norway, Spain, Romania, Turkey and United Kingdom. Germany and
Finland have subsequently become part of the validation project.
REFERENCES
1. Fex E, Larsson B, Nived K, et al. Effect of rheumatoid arthritis on work status and
social and leisure time activities in patients followed 8 years from onset. J Rheumatol
1998;25:44–50.
2. Sokka T, Kautiainen H, Mo¨tto¨nen T, et al. Work disability in rheumatoid arthritis 10
years after the diagnosis. J Rheumatol 1999;26:1681–5.
3. Barrett EM, Scott DGI, Wiles NJ, et al. The impact of rheumatoid arthritis on
employment status in the early years of disease: a UK community-based study.
Rheumatology 2000;39:1403–9.
4. Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and
increased mortality in seventy-five rheumatoid arthritis patients studied over nine
years. Arthritis Rheum 1984;27:864–72.
5. Wolfe F, Cathey MA. The assessment and prediction of functional disability in
rheumatoid arthritis. J Rheumatol 1991;18:1298–306.
6. So¨derlin MK, Nieminen P, Hakala M. Functional status predicts mortality in a
community based rheumatoid arthritis population. J Rheumatol 1998;25:1895–9.
7. Maiden N, Capell HA, Madhok R, et al. Does social disadvantage contribute to the
excess mortality in rheumatoid arthritis patients? Ann Rheum Dis 1999;58:525–9.
8. Sokka T, Hakkinen A, Krishnan E, et al. Similar prediction of mortality by the health
assessment questionnaire in patients with rheumatoid arthritis and the general
population. Ann Rheum Dis 2004;63:494–7.
9. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology
preliminary core set of disease activity measures for rheumatoid arthritis clinical trials.
The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis
Rheum 1993;36:729–40.
10. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008
recommendations for the use of nonbiologic and biologic disease-modifying
antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762–84.
11. Boers M, Tugwell P, Felson DT, et al. World Health Organization and International
League of Associations for Rheumatology core endpoints for symptom modifying
antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl
1994;41:86–9.
12. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology.
Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum
1995;38:727–35.
13. Prevoo ML, van’t Hof MA, Kuper HH, et al. Modified disease activity scores that
include twenty-eight-joint counts. Development and validation in a prospective
longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum
1995;38:44–8.
14. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for
rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford)
2003;42:244–57.
15. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite
disease activity indices for rheumatoid arthritis: validation of a clinical activity score.
Arthritis Res Ther 2005;7:R796–806.
16. Ma¨kinen H, Kautiainen H, Hannonen P, et al. A new disease activity index for
rheumatoid arthritis: Mean Overall Index for Rheumatoid Arthritis (MOI-RA).
J Rheumatol 2008;35:1522–7.
17. Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical
practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-
II). J Rheumatol 2005;32:2410–5.
18. Pincus T, Bergman MJ, Yazici Y, et al. An index of only patient-reported outcome
measures, routine assessment of patient index data 3 (RAPID3), in two abatacept
clinical trials: similar results to disease activity score (DAS28) and other RAPID
indices that include physician-reported measures. Rheumatology (Oxford)
2008;47:345–9.
19. Pincus T, Segurado OG. Most visits of most patients with rheumatoid arthritis to
most rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis
2006;65:820–2.
20. Pincus T, Strand V, Koch G, et al. An index of the three core data set patient
questionnaire measures distinguishes efficacy of active treatment from placebo as
effectively as the American College of Rheumatology 20% response criteria (ACR20)
or the disease activity score (DAS) in a rheumatoid arthritis clinical trial. Arthritis
Rheum 2003;48:625–30.
21. Pincus T, Yazici Y, Sokka T. Quantitative measures of rheumatic diseases for clinical
research versus standard clinical care: differences, advantages and limitations. Best
Pract Res Clin Rheumatol 2007;21:601–28.
22. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.
Conceptual framework and item selection. Med Care 1992;30:473–83.
23. Meenan RF, Mason JH, Anderson JJ, et al. AIMS2. The content and properties of a
revised and expanded Arthritis Impact Measurement Scales Health Status
Questionnaire. Arthritis Rheum 1992;35:1–10.
24. Kirwan J, Heiberg T, Hewlett S, et al. Outcomes from the Patient Perspective
Workshop at OMERACT 6. J Rheumatol 2003;30:868–72.
25. Carr A, Hewlett S, Hughes R, et al. Rheumatology outcomes: the patient’s
perspective. J Rheumatol 2003;30:880–3.
26. Kirwan JR, Hewlett SE, Heiberg T, et al. Incorporating the patient perspective into
outcome assessment in rheumatoid arthritis: progress at OMERACT 7. J Rheumatol
2005;32:2250–6.
27. Ahlmen M, Nordenskio¨ld U, Archenholtz B, et al. Rheumatology outcomes: the
patient’s perspective. A multicentre focus group interview study of Swedish
rheumatoid arthritis patients. Rheumatology 2005;44:105–10.
28. Stamm TA, Cieza A, Coenen M, et al. Validating the International Classification of
Functioning, Disability and Health Comprehensive Core Set for Rheumatoid Arthritis
from the patient perspective: a qualitative study. Arthritis Rheum 2005;53:431–9.
29. Coenen M, Cieza A, Stamm TA, et al. Validation of the International Classification of
Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis from the
patient perspective using focus groups. Arthritis Res Ther 2006;8:R84.
30. Lacaille D, White MA, Backman CL, et al. Problems faced at work due to
inflammatory arthritis: new insights gained from understanding patients’ perspective.
Arthritis Rheum 2007;57:1269–79.
31. Arnett FC, Edworthy SM, Block DA, et al. The American Rheumatism Association
1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum
1988;31:315–24.
32. Katz PA. Introduction to special patient outcomes in rheumatology issue of arthritis
care and research. Arthritis Rheum 2003;49:S1–4.
33. Kalyoncu U, Dougados M, Daure`s JP, et al. Reporting of patient-reported outcomes
in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis
2008 Mar 28. [Epub ahead of print]
34. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related
quality of life measures: literature review and proposed guidelines. J Clin Epidemiol
1993;46:1417–32.
35. Beaton DE, Bombardier C, Guillemin F, et al. Guidelines for the process of cross-
cultural adaptation of self-report measures. Spine 2000;25:3186–91.
36. Coste J, Walter E, Venot A. A new approach to selection and weighting of items in
evaluative composite measurement scales. Stat Med 1995;14:2565–80.
37. Ruta DA, Garratt AM, Leng M, et al. A new approach to the measurement of quality
of life. The Patient-Generated Index. Med Care 1994;32:1109–26.
38. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis.
Arthritis Rheum 1980;23:137–45.
39. Hewlett S, Hehir M, Kirwan JR. Measuring fatigue in rheumatoid arthritis: a
systematic review of scales in use. Arthritis Rheum 2007;57:429–39.
40. Pincus T, Summey JA, Soraci SA Jr, et al. Assessment of patient satisfaction in
activities of daily living using a modified Stanford Health Assessment Questionnaire.
Arthritis Rheum 1983;26:1346–53.
41. Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med
1991;32:705–14.
42. Holtzman S, Newth S, Delongis A. The role of social support in coping with daily pain
among patients with rheumatoid arthritis. J Health Psychol 2004;9:677–95.
43. Sokka T, Kautiainen H, Toloza S, et al. QUEST-RA: quantitative clinical assessment of
patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries.
Ann Rheum Dis 2007;66:1491–6.
44. Brady T. Measures of self-efficacy, helplessness, mastery and control. Arthritis
Rheum 2003;49:S147–64.
45. Heiberg T, Finset A, Uhlig T, et al. Seven year changes in health status and priorities
for improvement of health in patients with rheumatoid arthritis. Ann Rheum Dis
2005;64:191–5.
46. Heiberg T, Kvien TK. Preferences for improved health examined in 1,024 patients
with rheumatoid arthritis: pain has highest priority. Arthritis Rheum 2002;47:391–7.
47. Boers M, Brooks P, Strand CV, et al. The OMERACT filter for outcome measures in
rheumatology. J Rheumatol 1998;25:198–9.
48. Kvien TK, Heiberg T, Hagen KB. Minimal clinically important improvement/difference
(MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts
mean? Ann Rheum Dis 2007;66(Suppl 3):iii40–1.
Extended report
Ann Rheum Dis 2009;68:1680–1685. doi:10.1136/ard.2008.100271 1685
